Associated Papers
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
Bruckmueller H et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population.
Afsar NA et al.
Scientific Reports, 2019
Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation.
Tron C et al.
Clinical Pharmacokinetics, 2019
In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.
Wen X et al.
Pharmaceutical Research, 2017
Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study.
Nishijima T et al.
Plos One, 2015
MDR-1 and MRP2 Gene Polymorphisms in Mexican Epileptic Pediatric Patients with Complex Partial Seizures.
Escalante-Santiago D et al.
Frontiers in Neurology, 2014
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K et al.
Clinical Pharmacokinetics, 2013
Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.
Puranik YG et al.
Pharmacogenomics, 2013
Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital.
Subenthiran S et al.
Plos One, 2013
Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
Kim CO et al.
Journal of Cardiovascular Pharmacology, 2012
Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs.
Grover S et al.
Pharmacogenetics and Genomics, 2012
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
Cecchin E et al.
The Pharmacogenomics Journal, 2011
Analysis of pharmacogenetic traits in two distinct South African populations.
Ikediobi O et al.
Human Genomics, 2011
ABCC2 haplotype is not associated with drug-resistant epilepsy.
Seo T et al.
The Journal of Pharmacy and Pharmacology, 2008
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.
Naesens M et al.
Transplantation, 2006
Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
Ieiri I et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition.
Dey S
Expert Opinion on Drug Delivery, 2006
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Bosch TM et al.
Molecular Diagnosis & Therapy, 2006
Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28.
Itoda M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002